Associated Papers
Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.
Carnero-Gregorio M et al.
Genes, 2026
Resistance Mutation Profiles Associated with Current Treatments for Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer in the United States: A Systematic Literature Review.
Vadagam P et al.
Current Oncology (toronto, Ont.), 2025
Small Molecule B-RAF Inhibitors as Anti-Cancer Therapeutics: Advances in Discovery, Development, and Mechanistic Insights.
Anaya YA et al.
International Journal of Molecular Sciences, 2025
Real-World Evidence of the Prevalence of Driver Mutations in Anorectal Melanoma.
Jutten E et al.
Molecular Diagnosis & Therapy, 2025
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
Westphalen CB et al.
Esmo Open, 2023
Clinicopathological Features of Non-Small Cell Lung Carcinoma with BRAF Mutation.
Ambrosini-Spaltro A et al.
Current Oncology (toronto, Ont.), 2023
[Strategic Exploration of Targeted Therapy for BRAF Non-V600E Mutant Lung Cancer].
Zhang H et al.
Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer, 2022
Co-mutations of epidermal growth factor receptor and BRAF in Chinese non-small cell lung cancer patients.
Peng P et al.
Annals of Translational Medicine, 2021
Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer.
Fois SS et al.
International Journal of Molecular Sciences, 2021
Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.
Mack PC et al.
Cancer, 2020
Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
Pruis MA et al.
Lung Cancer (amsterdam, Netherlands), 2020
Identifying a wide range of actionable variants using capture-based ultra-deep targeted sequencing in treatment-naive patients with primary lung adenocarcinoma.
Chen L et al.
International Journal of Clinical and Experimental Pathology, 2020
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacological Research, 2018
Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells.
Testa U et al.
Cancers, 2018
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall.
Leonetti A et al.
Cancer Treatment Reviews, 2018
Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma.
Hou JY et al.
Cancer, 2017
Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response.
Li ZZ et al.
Oncotarget, 2016
BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?
Caparica R et al.
Critical Reviews in Oncology/hematology, 2016
The molecular profile of metastatic melanoma in Australia.
Lyle M et al.
Pathology, 2016
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.
Gautschi O et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2015
Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin.
Millis SZ et al.
Clinical Genitourinary Cancer, 2015
Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
Griewank KG et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2013
[Molecular profiling of non-small cell lung cancer].
Gibault L et al.
Revue De Pneumologie Clinique, 0